Where does Celgene Avilomics Research, Inc. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Celgene Avilomics Research, Inc. ranks #10,572 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Celgene Avilomics Research, Inc. hold?

Celgene Avilomics Research, Inc. holds 29 US utility patents granted between 2015 and 2017, spanning 10 technology areas.

What is Celgene Avilomics Research, Inc.'s Innovation Score?

Celgene Avilomics Research, Inc. has an Innovation Score of 37.9 out of 100 (top 42% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Celgene Avilomics Research, Inc. focus on?

Celgene Avilomics Research, Inc.'s top technology area is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations) with 27 patents, ranking #737 of 6,058 assignees active in that subclass. Grants appear in 10 CPC subclasses total.

Is Celgene Avilomics Research, Inc.'s patent grant rate increasing or decreasing?

Celgene Avilomics Research, Inc.'s recent grant velocity is -100% compared to the prior five-year period (grant years, not application filing dates). Grant activity has slowed relative to earlier years.

What does claim depth mean for Celgene Avilomics Research, Inc.'s patents?

Celgene Avilomics Research, Inc.'s patents average 25.5 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Celgene Avilomics Research, Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

Celgene Avilomics Research, Inc.

USPTO PatentsView assignee record - 29 granted patents across 10 technology areas, recorded in grant years 2015–2017. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Celgene ranks #10,572 of 49,997 tracked US assignees by granted-patent volume, with 29 patents across 10 technology areas.

#10,572
of 49,997 US assignees by volume: Top 42%
by Innovation Score (37.9/100): 25.5
avg claims per patent: -100%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R10572 · US Corporation #10,572 · 29 grants

GRANTS-SMALL · UPPER-Q · PHOTO-FINISH · CPC-FOCUS · INNOV-THIN · CLAIMS-DENSE · TYPE-USCORP · VEL-DROP · BOOK-FULL

GRANTS-SMALL 29 grants
UPPER-Q #10,572/49,997
PHOTO-FINISH Carma Technology
CPC-FOCUS A61P · 10 areas
INNOV-THIN 37.9/100
CLAIMS-DENSE 25.5 claims/avg
TYPE-USCORP US Corporation
VEL-DROP -100% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Carma Technology Ltd. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Celgene’s 37.9 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 11.7 pts (31%) Velocity 0.0 pts (0%) Breadth 11.2 pts (30%) Claim depth 15.0 pts (40%)

Qualcomm Incorporated · highest

85
Celgene Avilomics… · this assignee

38
InnerOptic Technology · near

38
Resman AS · near

38
SRI Sports · near

38
The Charlotte… · near

38
3D Lighting… · lowest

7

What this shows Celgene's Innovation Score is 37.9/100 (top 42% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Celgene?

Each dot is one of Celgene’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Celgene’s own 25.5 claims/patent is ABOVE the 11.6 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

Celgene vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Celgene's grants concentrate

Celgene Avilomics Research, Inc. is a focused PatentsView assignee: 10 CPC subclasses with 93.1% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). Peak complete grant year is 2016 (14 grants) versus a trough of 5 in 2017. By volume, Celgene sits between Cordis Corporation and Contrast, Inc..

Cordis

29
CP Delaware

29
CSR Technology Ho…

29
Carma Technology

29
Charles River Lab…

29
Clairson

29
Communications Te…

29
Contrast

29
Celgene Avilomics… ◀

29

What this shows Celgene holds 29 patents at rank #10,582, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Celgene

By rank, the assignees closest to #10,582 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in Celgene's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for Celgene, neither rank-band nor same-CPC leaders (those blocks stay above). In A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…), Celgene ranks #737 of 6,058 assignees by patent count in that subclass.

Similar innovation score

Nearest assignees by Innovation Score (38 here).

InnerOptic Technology, Inc. 38 Resman AS 38 The Charlotte Mecklenburg Hospital Authority 38 SRI Sports Limited 38

Celgene's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

38 Top 42% higher than 58% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2017

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

Celgene Avilomics Research, Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	10	34.5%
2016	14	48.3%
2017	5	17.2%

Which technologies does Celgene Avilomics Research, Inc. patent most?

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 27

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 26

C07D - Heterocyclic Compounds 25

C12N - Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media 7

C12Y - Enzymes 6

C07B - General Methods OF Organic CHEMISTRY; Apparatus Therefor 4

C07K - Peptides 4

C07F - Acyclic, Carbocyclic OR Heterocyclic Compounds Containing Elements Other Than Carbon, Hydrogen, Halogen, Oxygen, Nitrogen, Sulfur, Selenium OR Tellurium 3

C07C - Acyclic OR Carbocyclic Compounds 2

Y02P - Climate Change Mitigation Technologies IN THE Production OR Processing OF Goods 1

Top 10 of 10 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Celgene Avilomics Research, Inc.'s patent record in context - here's where to go next.

Celgene Avilomics Research, Inc.'s lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 93.1% of its portfolio - see every assignee active in that class. Explore A61P
Ranked #10,572 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Celgene Avilomics Research, Inc. against Cordis Corporation, an assignee filing at a similar volume. Compare portfolios
Innovation Score of 37.9/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.